These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Hyaline membrane disease (HMD) therapy in Latin America: impact of exogenous surfactant administration on newborn survival, morbidity and use of resources. Rossello JD; Hayward PE; Martell M; Del Barco M; Margotto P; Grandzoto J; Bastida J; Peña J; Villanueva D J Perinat Med; 1997; 25(3):280-7. PubMed ID: 9288665 [TBL] [Abstract][Full Text] [Related]
5. [Treatment of severe hyaline membrane disease with a single-dose of natural exogenous surfactant of porcine origin. A randomized trial: immediate effects and outcome at 28 days of life]. Walti H; Relier JP; Huon C; Monset-Couchard M; Scemama M; De Gamarra E; Moriette G; Curstedt T; Robertson B Arch Fr Pediatr; 1990 May; 47(5):329-34. PubMed ID: 2196030 [TBL] [Abstract][Full Text] [Related]
6. Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: a randomized trial at Ramathibodi Hospital. Supapannachart S; Limrungsikul A; Khowsathit P J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1252-8. PubMed ID: 12549803 [TBL] [Abstract][Full Text] [Related]
7. [Problems posed by the development of exogenous surfactants for the treatment of hyaline membrane disease]. Denizot BA; Tchoreloff PC; Bonanno LM; Proust JE; Lindenbaum A; Dehan M; Puisieux F Ann Pharm Fr; 1990; 48(5):242-7. PubMed ID: 2088159 [TBL] [Abstract][Full Text] [Related]
8. [Surgical treatment of the ductus arteriosus in premature infants]. Ochoa-Ramírez E; Puente-Ledezma JF; Hinojosa-Pérez JO; Cervantes F Gac Med Mex; 1983 Jul; 119(7):295-9. PubMed ID: 6680105 [No Abstract] [Full Text] [Related]
10. Early and late surfactant treatments in baboon model of hyaline membrane disease. Maeta H; Vidyasagar D; Raju TN; Bhat R; Matsuda H Pediatrics; 1988 Feb; 81(2):277-83. PubMed ID: 3340477 [TBL] [Abstract][Full Text] [Related]